|
November 7, 2022
|
Biora Therapeutics Announces $9.75 Million Direct Offering
|
|
October 27, 2022
|
Biora Therapeutics Announces Sale of Cell-Free DNA Patent Rights
|
|
October 25, 2022
|
Biora Therapeutics Shares Data from Device Performance Study in Ulcerative Colitis Patients
|
|
October 24, 2022
|
Biora Therapeutics Shares Five Posters Presented at American College of Gastroenterology Annual Scientific Meeting 2022
|
|
October 19, 2022
|
Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference
|
|
October 10, 2022
|
Biora Therapeutics to Participate in 12th Annual Partnership Opportunities in Drug Delivery Conference
|
|
September 13, 2022
|
Biora Therapeutics Announces Issuance of Key Patent for Oral Delivery of GLP-1 Receptor Agonists
|
|
September 7, 2022
|
Biora Therapeutics Appoints Dr. Bruce Sands as Chair of its Clinical Advisory Board
|
|
September 6, 2022
|
Biora Therapeutics to Participate in Upcoming H.C. Wainwright Investment Conference
|
|
August 15, 2022
|
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
|
